isoxazoles has been researched along with Dyslipidemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballon, JS; Contreras, I; Freyberg, R; Freyberg, Z; Leibel, RL; Lieberman, JA; Mayer, LE; Pajvani, UB; Rosenbaum, M | 1 |
| Fujioka, K | 1 |
| Agejas Francisco, J; Bocchinfuso, WP; Bueno, AB; Cannady, EA; Cox, A; Genin, MJ; Jones, TM; Manninen, PR; Michael, LF; Michael, MD; Montrose-Rafizadeh, C; Raddad, E; Reidy, C; Stille, JR | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
| Accili, D; Haeusler, RA; Klaassen, CD; Pratt-Hyatt, M; Welch, CL | 1 |
| Baldelli, F; Basile, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E | 1 |
1 review(s) available for isoxazoles and Dyslipidemia
| Article | Year |
|---|---|
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidemias; Epoxy Compounds; Humans; Hypertension; Isoxazoles; Obesity; Overweight; Prediabetic State; Sesquiterpenes; Weight Loss; Zonisamide | 2015 |
2 trial(s) available for isoxazoles and Dyslipidemia
| Article | Year |
|---|---|
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.
Topics: Adolescent; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Eating; Energy Metabolism; Female; Glucose Tolerance Test; Healthy Volunteers; Humans; Insulin; Insulin Resistance; Isoxazoles; Lipids; Male; Obesity; Olanzapine; Piperidines; Weight Gain; Young Adult | 2018 |
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Topics: Animals; Cholesterol; Dogs; Double-Blind Method; Dyslipidemias; Female; HEK293 Cells; Humans; Hypolipidemic Agents; Indoles; Isoxazoles; Macaca fascicularis; Male; Mice; Mice, Knockout; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Structure-Activity Relationship; Triglycerides | 2015 |
3 other study(ies) available for isoxazoles and Dyslipidemia
| Article | Year |
|---|---|
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |
Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia.
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Dyslipidemias; Forkhead Box Protein O1; Forkhead Transcription Factors; Glucose; Hydroxylation; Insulin; Isoxazoles; Lipid Metabolism; Liver; Male; Metabolome; Mice; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Steroid 12-alpha-Hydroxylase; Triglycerides | 2012 |
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dyslipidemias; Epididymis; Fatty Liver; HIV Protease Inhibitors; Isoxazoles; Leflunomide; Lipodystrophy; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Ritonavir | 2012 |